N Engl J Med:自体诱导干细胞产生的视网膜细胞用于治疗黄斑变性

2017-03-22 MedSci MedSci原创

研究人员评估了在新生血管性年龄相关性黄斑变性患者中,移植从诱导多能干细胞(iPSCs)中分离的视网膜色素上皮细胞(RPE)片的可行性。iPSC从两名晚期新生血管性年龄相关性黄斑变性患者的皮肤成纤维细胞产生,并分化为RPE细胞。RPE细胞和共同来源的iPSC经过严格的测试。在其中一位患者中进行包括去除新生血管膜,并在视网膜下移植自体iPSC衍生的RPE细胞片的手术。手术后1年,移植片保持完整,矫正视

最近,来自日本理化研究所(RIKENMasayo Takahashi领导的研究团队报道了关于干细胞临床试验治疗黄斑变性的研究, 相关研究成果刊登于国际权威杂志N Engl J Med上。

干细胞是一类未完全分化且具有再生各种组织器官潜在功能的细胞。干细胞可用于修复特定的组织或生长器官,具有开发成人类疾病治疗的新方法的巨大前景。

研究人员评估了在新生血管性年龄相关性黄斑变性患者中移植从诱导多能干细胞(iPSCs)中分离的视网膜色素上皮细胞(RPE)片的可行性。iPSC从两名晚期新生血管性年龄相关性黄斑变性患者的皮肤成纤维细胞产生,并分化为RPE细胞。RPE细胞和共同来源的iPSC经过严格的测试。在其中一位患者中进行包括去除新生血管膜,并在视网膜下移植自体iPSC衍生的RPE细胞片的手术。手术后1年,移植片保持完整,矫正视力最佳既没有改善也未变差,尽管出现了囊性黄斑水肿。

该研究首次表明iPSC临床应用是相对安全的。

研究由实现再生医学高等项目资助;大学医院医学信息网络临床试验注册[UMIN-CTR]号码为UMIN000011929

原始出处:

Michiko Mandai, M.D., Ph.D., Akira Watanabe, Ph.D. Masayo Takahashi.et al.Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration. N Engl J Med 2017; 376:1038-1046March 16, 2017DOI: 10.1056/NEJMoa1608368

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1785445, encodeId=7d931e854456b, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 17 10:21:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081342, encodeId=427820813421d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Dec 20 20:21:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269852, encodeId=0438126985244, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463524, encodeId=62b014635244a, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525078, encodeId=b1f115250e8ba, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607322, encodeId=7a2e160e32251, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-06-17 haouestc
  2. [GetPortalCommentsPageByObjectIdResponse(id=1785445, encodeId=7d931e854456b, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 17 10:21:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081342, encodeId=427820813421d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Dec 20 20:21:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269852, encodeId=0438126985244, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463524, encodeId=62b014635244a, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525078, encodeId=b1f115250e8ba, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607322, encodeId=7a2e160e32251, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-12-20 spoonycyy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1785445, encodeId=7d931e854456b, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 17 10:21:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081342, encodeId=427820813421d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Dec 20 20:21:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269852, encodeId=0438126985244, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463524, encodeId=62b014635244a, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525078, encodeId=b1f115250e8ba, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607322, encodeId=7a2e160e32251, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1785445, encodeId=7d931e854456b, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 17 10:21:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081342, encodeId=427820813421d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Dec 20 20:21:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269852, encodeId=0438126985244, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463524, encodeId=62b014635244a, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525078, encodeId=b1f115250e8ba, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607322, encodeId=7a2e160e32251, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 huangdf
  5. [GetPortalCommentsPageByObjectIdResponse(id=1785445, encodeId=7d931e854456b, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 17 10:21:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081342, encodeId=427820813421d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Dec 20 20:21:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269852, encodeId=0438126985244, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463524, encodeId=62b014635244a, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525078, encodeId=b1f115250e8ba, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607322, encodeId=7a2e160e32251, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]
    2017-03-24 muzishouyi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1785445, encodeId=7d931e854456b, content=<a href='/topic/show?id=34b86e91f9' target=_blank style='color:#2F92EE;'>#Engl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6791, encryptionId=34b86e91f9, topicName=Engl)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Sat Jun 17 10:21:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081342, encodeId=427820813421d, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Wed Dec 20 20:21:00 CST 2017, time=2017-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269852, encodeId=0438126985244, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463524, encodeId=62b014635244a, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525078, encodeId=b1f115250e8ba, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607322, encodeId=7a2e160e32251, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 24 05:21:00 CST 2017, time=2017-03-24, status=1, ipAttribution=)]

相关资讯

NEJM:重磅齐发:临床试验一成一败,干细胞治疗还能好吗?

昨天,两篇有关干细胞临床试验治疗黄斑变性的文章同时发表在权威期刊《新英格兰医学杂志》上,但是他们的结果却截然不同!

STM:基因改造过的诱导性多功能干细胞(iPSCs)可治疗隐性遗传营养不良型大疱性表皮松解症(RDEB)

隐性遗传营养不良型大疱性表皮松解症(RDEB) 是一种遗传疾病。它是由于VII型胶原的编码基因变异导致的。RDEB患者的皮肤很脆弱并且很容易在接收到压力时起水疱。特别是对于RDEB这种在现阶段没有有效治疗的疾病,使用诱导性多功能干细胞(iPSCs)有从根本上改变疾病细胞治疗的潜力。为了证明诱导性多功能干细胞(iPSCs)可以治疗RDEB,研究者们从有VII型胶原基因(Co17a1)变异的小鼠中提取

Nature:重编程细胞同源移植也会发生排斥反应

6月9日出版的自然杂志继5月刊发加州大学圣地亚哥分校的研究人员有关诱导多能干细胞(iPSCs)论文,再次刊登有关该研究的一篇快报,并予以评论,称研究人员在小鼠中证实将诱导多能干细胞(iPSCs)分化生成的多种组织移植至动物体内会产生快速的免疫排斥反应,即便iPSCs的起源细胞来自于移植小鼠本身。一直以来,大多数科学家们都认为来自于个人自身组织的重编程细胞能够被安全地移植到同一个体体内并能避免排斥反